Announcement • Aug 03
Aptevo Therapeutics Inc., Annual General Meeting, Aug 21, 2026 Aptevo Therapeutics Inc., Annual General Meeting, Aug 21, 2026. Announcement • Jul 28
Aptevo Therapeutics Inc. Announces New Solid Tumor Strategy and Filing of Patent Application Covering Proprietary Nectin-4 X PD-L1 Dual-Targeting Backbone Aptevo Therapeutics Inc. announced a new solid tumor strategy and the filing of a patent application covering a proprietary Nectin-4 x PD-L1 dual-targeting backbone. The technology is designed to strengthen its oncology pipeline, support multiple therapeutic approaches from a single platform-derived innovation, and expand potential partnering opportunities. The Company has filed a patent application covering a proprietary Nectin-4 x PD-L1 dual-targeting backbone designed to strengthen Aptevo's oncology pipeline, expand partnering opportunities and support multiple therapeutic approaches from a single platform-derived innovation. Instead of pursuing one product built for one use, the filing will protect a backbone that may be adapted into multiple cancer-fighting approaches. The backbone is designed to be adapted into radiopharmaceuticals, T-cell engagers and other immune-based approaches using a versatile platform approach. The backbone is designed to recognize two important targets in solid tumors, Nectin-4 and PD-L1, and to give a foundation that can be built on in multiple ways. The Company notes that radiopharmaceutical therapy is one potential application of this strategy and an area of growing focus for Aptevo. Pairing tumor-targeting constructs with radioligands supports the development of new targeted radiopharmaceutical candidates designed to deliver treatment activity directly to tumors. The Nectin-4 x PD-L1 backbone may also support T-cell engagers and other immune-based therapies, giving Aptevo multiple ways to pursue solid tumors through tumor targeting, immune activation and payload delivery. The approach is designed to help therapies find tumors more precisely and simultaneously enhance anti-tumor immunity. Nectin-4 is found on several solid tumors, and PD-L1 can be found both on tumor cells and immune-suppressing cells within the tumor. By targeting both, Aptevo aims to direct treatment activity more selectively where it is needed most, better avoiding normal tissues than single-targeted agents. In addition to enhanced tumor localization, targeting PD-L1 immune-suppressing cells will enhance anti-tumor immunity. From here, Aptevo can deepen anti-tumor efficacy by adding additional functional components. The backbone also demonstrates how Aptevo's ADAPTIR and ADAPTIR-FLEX platforms are used to build smarter, more flexible cancer therapies. Aptevo can adjust how each construct is designed and add different therapeutic components depending on the goal. The same targeting concept may be used to create different kinds of therapies for hard-to-treat solid tumors. The filing strengthens Aptevo's intellectual property portfolio and supports a focused, platform-driven strategy: use proprietary science to create multiple shots on goal, retain strategic control and open the door to collaborations that could accelerate development. Announcement • May 29
Aptevo Therapeutics Inc. Appoints Mary J. Janatpour as Senior Vice President & Chief Scientific Officer Aptevo Therapeutics Inc. announced the appointment of Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer. Dr. Janatpour brings more than 25 years of oncology research and development leadership across biotechnology and pharmaceutical organizations, with deep expertise spanning target discovery, translational science, and pipeline strategy. In this role, she will lead Aptevo's research and preclinical development efforts and play a key role in advancing the Company's expanding pipeline of multispecific therapeutics. Dr. Janatpour has held senior scientific leadership roles across both large biopharmaceutical organizations and emerging biotechnology companies, giving her a rare combination of deep oncology research expertise and hands-on experience building innovative programs in fast-moving development environments. Earlier in her career, she held leadership positions at the Novartis Institutes for Biomedical Research, Schering-Plough Biopharma and Chiron, where her work focused on oncology biologics target identification and validation. The latter half of her career has been focused on immuno-oncology, where she has led oncology discovery and translational strategy for established and emerging biotechnology companies advancing novel therapeutic molecules and platforms. Across her career, Dr. Janatpour has helped shape and advance multiple oncology portfolios spanning early discovery through clinical translation, with expertise in immuno-oncology, antibody-based therapeutics and innovative platform technologies. She has also served as a scientific advisor and board member to several biotechnology organizations. Dr. Janatpour holds a Ph.D. in Biomedical Sciences from the University of California, San Francisco, and completed her postdoctoral training in Immunology at the DNAX Research Institute. Announcement • Mar 14
Aptevo Therapeutics Inc Announces New Interim Data For Mipletamig In Combination With Venetoclax And Azacitidine Aptevo Therapeutics Inc. announced new interim data for mipletamig in combination with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia (AML) patients who are either elderly or unfit for intensive chemotherapy. In data from two trials, the combination has demonstrated robust clinical activity, delivering an 86% clinical benefit rate (CR/CRi/PR*) with zero patients experiencing the common symptom of cytokine release syndrome (CRS). These data support an emerging efficacy profile coupled with differentiated patient safety and tolerability that is additive to the current AML standard-of-care therapy. Among the evaluable frontline patient population treated to date (N=28), including 24 patients from the RAINIER trial and 4 patients from the completed dose expansion trial, mipletamig in combination with venetoclax and azacitidine has demonstrated: 100% of frontline patients have remained free of cytokine release syndrome (CRS), 86% clinical benefit rate, 79% achieved CR or CRi, 61% achieved CR, 55% of patients who achieved CR/CRi had blast reductions that reached the important measurable residual disease-negative level, a result that is typically associated with stronger, more durable responses, 35% of patients with remissions had the TP53 genetic mutation, a high-risk biomarker typically associated with poor prognosis in AML and for which most treatment options frequently fail. Collectively, these data demonstrate mipletamigs potential to meaningfully enhance frontline AML treatment in older and/or unfit patients, by improving efficacy outcomes without materially increasing toxicity. RAINIER, a frontline AML study, is a Phase 1b/2 dose optimization, multi-center, multi-cohort, open label study. Subjects are adults aged 18 or older, newly diagnosed with AML who are not eligible for intensive induction chemotherapy. RAINIER will be conducted in two parts. First, a Phase 1b dose optimization study in frontline AML patients followed by a Phase 2 study. The Phase 1b trial consists of 28-day cycles of treatment across multiple, sequential cohorts. Aptevo's wholly owned lead proprietary drug candidate, mipletamig, being evaluated for the treatment of AML, is differentiated by design to redirect the immune system of the patient to destroy leukemic cells and leukemic stem cells expressing the target antigen CD123, which is a compelling target for AML due to its overexpression on leukemic stem cells and AML blasts. This antibody-like recombinant protein therapeutic is designed to engage both leukemic cells and T cells of the immune system and bring them closely together to trigger the destruction of leukemic cells. Mipletamig is purposefully designed to reduce the likelihood and severity of CRS by use of the CRIS-7-derived CD3 binding pathway, an approach that differentiates Aptevo from competitors. Mipletamig has received orphan drug designation ("orphan status") for AML according to the Orphan Drug Act. Orphan drug designation provides key advantagesincluding the opportunity to seek U.S. market exclusivity for a specific period of time upon approval, FDA fee reductions, and access to development and tax credits. Mipletamig has been evaluated in more than 120 patients over three trials to date. In frontline patients treated to date, no cytokine release syndrome (CRS) has been observed. Together with strong efficacy outcomes, this outcome underscores mipletamigs safety and combinability, potentially offering a superior treatment in the future. This safety profile is particularly important in frontline AML, where tolerability and combinability are essential for treating older patients and/or those with comorbidities. New Risk • Mar 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (over 245x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (US$6.72m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$29m net loss in 3 years). 
